Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.39 |
| ▸ | RARA | P10276 | 4/20 | 0.39 |
| ▸ | RARB | P10826 | 4/20 | 0.39 |
| ▸ | RARG | P13631 | 4/20 | 0.39 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31723134 | 1.00 | MCL1 (0.46) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL28895627 | 0.87 | MEN1 (0.48) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL31723178 | 0.87 | MEN1 (0.48) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL28824884 | 0.86 | MEN1 (0.47) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL31723170 | 0.85 | MEN1 (0.46) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL20918209 | 0.85 | MEN1 (0.46) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL20918264 | 0.84 | KDM4E (0.56) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL28429215 | 0.84 | MEN1 (0.49) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL31723147 | 0.84 | KDM4E (0.56) | MCL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL14266219 | 0.83 | ALDH1A1 (0.58) | MCL1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2023-12-26 | — | — | US | claimed |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2023-03-30 | — | — | US | claimed |
| US-11504349-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2022-11-22 | — | — | US | claimed |
| EP-3699174-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2020-08-26 | — | — | EP | claimed |
| US-20200246304-A1 | Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same | ILAB (KR) | 2020-08-06 | — | — | US | claimed |
| CN-111315730-A | Composition for preventing or treating tumor necrosis factor-related diseases comprising novel derivative as active ingredient and method for inhibiting tumor necrosis factor activity using the same | 艾伊莱布 | 2020-06-19 | — | — | CN | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | disclosed |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2023-12-26 | — | — | US | disclosed |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2023-03-30 | — | — | US | disclosed |
| US-11504349-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2022-11-22 | — | — | US | disclosed |
| EP-3699174-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2020-08-26 | — | — | EP | disclosed |
| US-20200246304-A1 | Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same | ILAB (KR) | 2020-08-06 | — | — | US | disclosed |
| CN-111315730-A | Composition for preventing or treating tumor necrosis factor-related diseases comprising novel derivative as active ingredient and method for inhibiting tumor necrosis factor activity using the same | 艾伊莱布 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019078452-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | 가톨릭대학교 산학협력단 | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | TNF, NFKBIA, TRAF6 | MCL1 3398/4885MEN1 4570/4885KMT2A 4786/4885 |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | TNF, NFKBIA, TRAF6 | MCL1 3398/4885MEN1 4570/4885KMT2A 4786/4885 |
| US-20200246304-A1 | Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same | TNF, NFKBIA, TRAF6 | MCL1 3398/4885MEN1 4570/4885KMT2A 4786/4885 |
| US-11504349-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | TNF, NFKBIA, TRAF6 | MCL1 3398/4885MEN1 4570/4885KMT2A 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.